Sign in

CIK 0001618835

  • Non-accelerated filer
  • Smaller reporting company

Evofem Biosciences, Inc.

Sign in to watch
Ticker
EVFM
Exchange
OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
208527075
Phone
+1 858-550-1900
Business address
12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130
Former names
Neothetics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market buy Chief Executive Officer bought 45,249 shares at $2.28 ($103,168)
  3. 4 Grant or award Chief Executive Officer acquired 500,000 shares (grant or award)
  4. 4 Grant or award Chief Commercial Officer acquired 200,000 shares (grant or award)
  5. 4 Grant or award Chief Financial Officer acquired 200,000 shares (grant or award)
  6. 4 Grant or award General Counsel and Secretary acquired 200,000 shares (grant or award)
  7. 4 Grant or award Chief Medical Officer acquired 200,000 shares (grant or award)
  8. 4 Open-market buy Chief Financial Officer bought 7,760 shares at $2.17 ($16,839)
  9. 4 Open-market buy General Counsel and Secretary bought 9,090 shares at $2.20 ($19,998)
  10. 4 Open-market buy Chief Commercial Officer bought 4,000 shares at an average $2.24 ($8,950)
  11. 4 Open-market sale Chief Executive Officer sold 122,500 shares at $3.26 ($399,350)
  12. 4 Open-market sale 10% owner sold 9,138,504 shares at $0.23 ($2,101,856)
  13. 4 Shares withheld for taxes Chief Commercial Officer gave up 20,381 shares (to pay taxes)
  14. 4 Open-market buy Director bought 5,250 shares at $2.99 ($15,698)
  15. 4/A Open-market buy Director bought 5,000 shares at $2.85 ($14,250)
  16. 4 Open-market buy Director bought 5,000 shares at $2.85 ($14,250)
  17. 4 Open-market buy Director bought 5,000 shares at $2.94 ($14,700)
  18. 4 Open-market buy Chief Financial Officer bought 8,500 shares at $3.14 ($26,690)
  19. 4 Open-market sale 10% owner sold 9,138,504 shares at $3.21 ($29,325,459)
  20. 3 Insider Initial Statement of Ownership

Page 3 of 15 · 281 filings